Company / Current Assets
Anixa Biosciences Inc Current Assets History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$21.4M
FY2024
5-year range
$6.1M / $30.2M
FY2020-FY2024
Trend
-15.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has fluctuated over the past 10 years, ranging from $3M in FY2016 to $30M in FY2022.
Based on SEC 10-K filings.
$21M in FY2024 with a 10-year CAGR of +12.9%.
Declined from $30M to $21M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +28.5%
- 10-Year CAGR
- +12.9%
Key checks
Key Insights
- 5-year CAGR of +28.5%, indicating consistent growth.
- In FY2024, current assets decreased 15.8% year-over-year.
- Peak current assets was recorded in FY2022.
- Lowest current assets in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $21.4M | -15.8% |
| FY2023 | $25.4M | -16.0% |
| FY2022 | $30.2M | +222.4% |
| FY2020 | $9.4M | +53.8% |
| FY2019 | $6.1M | +10.0% |
| FY2018 | $5.5M | -21.0% |
| FY2017 | $7.0M | +106.3% |
| FY2016 | $3.4M | -50.7% |
| FY2015 | $6.9M | +9.1% |
| FY2014 | $6.3M | +585.6% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026